RSS   Newsletter   Contact   Advertise with us
Post Online Media

Roche enters into definitive merger agreement to acquire Spark Therapeutics

Share on Twitter Share on LinkedIn
Staff Writer |
Roche
Acquisition   This price represents a premium of approximately 122%

Roche and Spark Therapeutics announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction.


This corresponds to a total transaction value of approximately US$ 4.3 billion on a fully diluted basis.

This price represents a premium of approximately 122% to Spark Therapeutics’ closing price on 22 February 2019 and a premium of approximately 19% to Spark Therapeutics’ 52 week high share price on 9 July 2018. The merger agreement has been unanimously approved by the boards of Spark Therapeutics and Roche.

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark Therapeutics common stock, and Spark Therapeutics will file a recommendation statement containing the unanimous recommendation of the Spark Therapeutics board that Spark Therapeutics’ shareholders tender their shares to Roche.

Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, haemophilia, lysosomal storage disorders and neurodegenerative diseases.


What to read next
POST Online Media Contact